The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection
Author(s)
Type
Journal Article
Abstract
Antibiotics are widely used in the treatment of bacterial infections. Although known for their microbicidal activity, antibiotics may also interfere with the host's immune system. Here, we analyzed the effects of bedaquiline (BDQ), an inhibitor of the mycobacterial ATP synthase, on human macrophages. Genome-wide gene expression analysis revealed that BDQ reprogramed cells into potent bactericidal phagocytes. We found that 579 and 1,495 genes were respectively differentially expressed in naive- and M. tuberculosis-infected macrophages incubated with the drug, with an over-representation of lysosome-associated genes. BDQ treatment triggered a variety of antimicrobial defense mechanisms, including phagosome-lysosome fusion, and autophagy. These effects were associated with activation of transcription factor EB, involved in the transcription of lysosomal genes, resulting in enhanced intracellular killing of different bacterial species that were naturally insensitive to BDQ. Thus, BDQ could be used as a host-directed therapy against a wide range of bacterial infections.
Date Issued
2020-05-04
Date Acceptance
2020-04-04
Citation
eLife, 2020, 9
ISSN
2050-084X
Publisher
eLife Sciences Publications Ltd
Journal / Book Title
eLife
Volume
9
Copyright Statement
© 2020, Giraud-Gatineau et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/32369020
PII: 55692
Subjects
antibiotics
host-pathogen interaction
human
immunology
infectious disease
inflammation
innate immunity
macrophages
microbiology
tuberculosis
Publication Status
Published
Coverage Spatial
England
Article Number
ARTN e55692